Gilead Sciences Inc. announced amendments to its bylaws, effective July 30, 2025. The changes include updates to procedural and disclosure requirements for director nominations and proposal submissions at stockholder meetings, revisions to majority vote provisions, and clarifications on board vacancies and meeting conduct. Additionally, the amendments address emergency provisions, align with recent Delaware law changes, and enhance compliance with federal proxy regulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.